NCT05314140View on ClinicalTrials.gov

Towards Optimal Screening and Management of Coronary Artery Disease in Diabetes: TOSCANA Study

Not yet recruitingOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Diabetes MellitusCardiovascular Diseases
Interventions
DIAGNOSTIC_TEST

Coronary artery calcium score evaluation

The evaluation of the coronary artery calcium score will be performed with chest CT scan

Trial Locations (9)

33000

CHU de Bordeaux, Bordeaux

37000

CHU de Tours, Tours

57100

Centre de Cardiologie de Thionville, Thionville

75010

Hôpital Lariboisière, APHP, Paris

75012

Hopital Saint Antoine, Paris

86000

CHU de Poitiers, Poitiers

87000

CHU de Limoges, Limoges

97400

CHU de la Réunion, Saint-Denis

06000

CHU de Nice, Nice

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

collaborator

CEBIMER

UNKNOWN

lead

French Cardiology Society

OTHER

NCT05314140 - Towards Optimal Screening and Management of Coronary Artery Disease in Diabetes: TOSCANA Study | Biotech Hunter | Biotech Hunter